[go: up one dir, main page]

ATE173763T1 - Hybride cytokine - Google Patents

Hybride cytokine

Info

Publication number
ATE173763T1
ATE173763T1 AT92918688T AT92918688T ATE173763T1 AT E173763 T1 ATE173763 T1 AT E173763T1 AT 92918688 T AT92918688 T AT 92918688T AT 92918688 T AT92918688 T AT 92918688T AT E173763 T1 ATE173763 T1 AT E173763T1
Authority
AT
Austria
Prior art keywords
cytokines
hybrid
derived
regions
treating conditions
Prior art date
Application number
AT92918688T
Other languages
English (en)
Inventor
George J Todaro
Timothy M Rose
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Application granted granted Critical
Publication of ATE173763T1 publication Critical patent/ATE173763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Dry Shavers And Clippers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92918688T 1991-08-30 1992-08-24 Hybride cytokine ATE173763T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75317891A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
ATE173763T1 true ATE173763T1 (de) 1998-12-15

Family

ID=25029503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918688T ATE173763T1 (de) 1991-08-30 1992-08-24 Hybride cytokine

Country Status (9)

Country Link
US (1) US6204364B1 (de)
EP (1) EP0601043B1 (de)
JP (1) JPH06510202A (de)
AT (1) ATE173763T1 (de)
AU (1) AU666866B2 (de)
CA (1) CA2116533A1 (de)
DE (1) DE69227693T2 (de)
NZ (1) NZ244155A (de)
WO (1) WO1993005169A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6171824B1 (en) * 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
WO1994003492A1 (en) * 1992-08-06 1994-02-17 The University Of Melbourne Interleukin-6 variants and uses therefor
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0746569A4 (de) * 1993-02-03 1999-03-24 Amrad Corp Ltd Rezeptor-bindende determinante des leukämie hemmendenfaktors
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
JPH11500308A (ja) * 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
NZ505037A (en) * 1997-12-10 2002-05-31 Zymogenetics Inc Mammalian alpha helical protein-1 (Zalpha1)
US6303770B1 (en) 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6329789B1 (en) * 1999-12-21 2001-12-11 Moltech Corporation Methods of charging lithium-sulfur batteries
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2412845C (en) 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002090566A2 (en) 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
MXPA04000231A (es) * 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
CA2503330A1 (en) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
EP2364716A3 (de) * 2002-11-08 2012-01-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
PT1572748E (pt) 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
DK1699821T3 (da) 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
EP1819728B1 (de) 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7-varianten mit reduzierter immunogenität
US7381805B2 (en) * 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
DK1966245T3 (da) 2005-12-30 2011-07-18 Merck Patent Gmbh Anti-CD19-Antistoffer med reduceret immunogenicitet
DK1966238T3 (da) 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE69007975T2 (de) * 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.

Also Published As

Publication number Publication date
DE69227693D1 (de) 1999-01-07
DE69227693T2 (de) 1999-07-22
AU2500392A (en) 1993-04-05
US6204364B1 (en) 2001-03-20
EP0601043A4 (de) 1995-05-10
EP0601043A1 (de) 1994-06-15
AU666866B2 (en) 1996-02-29
JPH06510202A (ja) 1994-11-17
CA2116533A1 (en) 1993-03-18
NZ244155A (en) 1994-11-25
WO1993005169A1 (en) 1993-03-18
EP0601043B1 (de) 1998-11-25

Similar Documents

Publication Publication Date Title
DE69227693D1 (de) Hybride cytokine
ZA869269B (en) Insecticidal pyrazolines
EP0273169A3 (de) Antivirale Wirkstoffe
IT8820593A0 (it) Complesso di palette direttrici variabili per compressore.
CS414591A3 (en) Cytokinin synthesis inhibition factor, antagonists thereof and its use
HU911529D0 (en) Mutants of granulocyte colony stimulating factor (g-csf)
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
MY105344A (en) New sulphonyl compounds
ES8500727A1 (es) Procedimiento para la obtencion de derivados de feniletilamina
BG35330A3 (en) Method for preparing 3- iodine- methylcephalosporines
BG34901A3 (en) Means for plant growth regulation
DK12990A (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
IT8519848A0 (it) Disposizione di grappoli di barre di regolazione.
IT8219484A0 (it) Struttura di banco modulare componibile per il supporto particolarmente di accumulatori.
DK187785A (da) Chartreusinderivater og salte deraf, fremgangsmaade til fremstillingaf disse og antitumorpraeparater indeholdende saadanne forbindelser
ATE239496T1 (de) Gleichzeitige verabreichung von interleukin 3 mutantpolypeptiden mit csf faktoren für die hematopoietische multi-zelllinien herstellung
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
FR2680773B1 (fr) Chariot de manutention dont la stabilite est renforcee par repartition isostatique des charges aux appuis.
EP0226259A3 (de) Kationisches Komplex von Technetium-99m
DE68922571D1 (de) N-Sulfenylierte und N-acylierte Pyrazoline.
MY105868A (en) Treatment of myelosuppression associated with acquired immune deficiency.
BG35895A3 (en) Method for preparing of n- substituted- 2- haloacetanilides
ES8802309A1 (es) Procedimiento para la obtencion de piridiletil-dihidropiridinas
BG35041A3 (en) Method for preparing substituted 2- piperadine- 4- amino- 6, 7- dimetoxyquinazolines
ES8308652A1 (es) Bloque condensador electrico perfeccionado.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties